Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11933500 | 1.00 | CNR1 (0.32) | CNR1CNR2CYP2C9THRBPTPN1 | |
| SCHEMBL11933502 | 0.99 | CNR1 (0.33) | CNR1CNR2CYP2C9THRBPTPN1 | |
| SCHEMBL11933546 | 0.99 | CNR1 (0.33) | CNR1CNR2CYP2C9THRBPTPN1 | |
| SCHEMBL11933506 | 0.97 | SCN9A (0.32) | CNR1CNR2SCN9A | |
| SCHEMBL11933543 | 0.97 | SCN9A (0.32) | CNR1CNR2SCN9A | |
| SCHEMBL11933499 | 0.95 | CNR1 (0.30) | CNR1CNR2 | |
| SCHEMBL11933542 | 0.95 | CNR1 (0.30) | CNR1CNR2 | |
| SCHEMBL18175604 | 0.94 | CNR2 (0.33) | CNR1CNR2CYP2C9THRBPTPN1 | |
| SCHEMBL18175624 | 0.94 | CNR2 (0.33) | CNR1CNR2CYP2C9THRBPTPN1 | |
| SCHEMBL18175601 | 0.94 | CNR1 (0.35) | CNR1CNR2CYP2C9THRBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580147-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | CNR1 254/4885CNR2 474/4885CYP2C9 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.